Early Drug Safety Strategies Using In Vivo Fluorescence Imaging


Drug development faces a significant challenge in that only 1 in 10 candidates make it to the market, often due to safety/toxicity issues rather than efficacy. Adoption of early assessments to de-risk drug candidates by identifying and de-prioritizing those with potential safety issues is of paramount importance.

Watch this on demand webinar presented by Dr. Jeff Peterson, Director of Applied Biology at PerkinElmer, where he discussed how in vivo fluorescence probes and strategies can be used in early drug screening.